Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Many claims are either not supported by the provided labeling excerpts (e.g., generic/patent status, remission, comparative efficacy/response speed, imatinib sequencing/usage language, specific side-effect frequency wording, and dose frequency as “typically once daily” without context) or are potentially misleading. While core mechanism/indications and several safety concepts align with the label excerpts, numerous unsupported or overly specific statements substantially reduce alignment.
Category Scores
Accurate Statements
Dasatinib is a medication used to treat certain types of chronic myeloid leukemia (CML).
Label 1 indicates treatment of adult newly diagnosed Ph+ CML (chronic phase) and Ph+ CML with resistance/intolerance to prior therapy in chronic, accelerated, or blast phases.
Dasatinib is a medication used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Label 1 indicates Ph+ ALL with resistance or intolerance to prior therapy; also pediatric newly diagnosed Ph+ ALL in combination with chemotherapy.
Dasatinib is a tyrosine kinase inhibitor.
Label 11/12 describes SPRYCEL as a kinase inhibitor; label 12.1 states mechanism as inhibiting kinases.
Dasatinib inhibits the activity of specific tyrosine kinases, including BCR-ABL.
Label 12.1 mechanism includes inhibition of BCR-ABL.
Dasatinib inhibits the activity of specific tyrosine kinases, including SRC family kinases.
Label 12.1 mechanism includes inhibition of SRC family kinases.
Fluid retention (edema) is a common side effect of dasatinib.
Label 5.3/6 indicates fluid retention as a warning/adverse reaction topic; however “common” frequency is not supported in provided excerpts.
Shortness of breath is a common side effect of dasatinib.
Not supported by provided excerpts (no frequency statement or dyspnea listing provided in excerpts).
Dasatinib is usually taken orally.
Label 2 states tablets are administered orally once daily.
Dosage of dasatinib can vary depending on the type and stage of leukemia being treated.
Label 2.1 specifies different starting doses for chronic phase CML vs accelerated/blast phase CML or Ph+ ALL.
Dosage of dasatinib can vary depending on the patient's response to the medication.
Label excerpts include dose modification concepts; but “response-based” phrasing is not explicitly shown in provided text.
Clinical trials have established the efficacy of dasatinib in treating CML.
Label 14.1/14.3 describe randomized/evaluated studies with efficacy endpoints.
Clinical trials have established the efficacy of dasatinib in treating Ph+ ALL.
Label 1 and label 14.4/14.2 describe efficacy evaluation in Ph+ ALL.
Stopping dasatinib treatment can lead to relapse of the leukemia.
Not supported in provided excerpts; label excerpt provided does not state relapse upon discontinuation.
Unsupported Statements
The primary patents for dasatinib have expired.
No patent/market exclusivity status information in provided label excerpts.
Generic versions of dasatinib are available due to expiration of key patents.
No generic availability/patent expiration information in provided label excerpts.
Generic drugs are designed to be bioequivalent to the brand-name medication.
Not addressed in provided label excerpts.
Generic versions are expected to have the same safety and efficacy profile as the brand-name medication.
Not addressed in provided label excerpts.
BCR-ABL is often overactive in CML and Ph+ ALL.
Label mechanism supports BCR-ABL involvement but does not state “often overactive” in the provided excerpts.
SRC family kinases are often overactive in CML and Ph+ ALL.
Label mechanism lists SRC family kinases but provided excerpts do not state “often overactive” or disease-specific overactivity.
Dasatinib helps to slow down or stop the proliferation of cancerous cells.
No such wording in provided excerpts.
Dasatinib can lead to remission.
Provided excerpts do not use or support “remission” as a claim.
Generic/brand comparative frequency statements: Fluid retention (edema) is a common side effect of dasatinib.
Label excerpt does not provide frequency characterization (e.g., “common”) for fluid retention.
Shortness of breath is a common side effect of dasatinib.
No dyspnea/shortness of breath adverse reaction frequency or mention in provided excerpts.
Diarrhea is a common side effect of dasatinib.
No diarrhea adverse reaction or frequency in provided excerpts.
Headache is a common side effect of dasatinib.
No headache adverse reaction or frequency in provided excerpts.
Rash is a common side effect of dasatinib.
No rash adverse reaction or frequency in provided excerpts.
Fatigue is a common side effect of dasatinib.
No fatigue adverse reaction or frequency in provided excerpts.
Nausea is a common side effect of dasatinib.
No nausea adverse reaction or frequency in provided excerpts.
Muscle cramps are a common side effect of dasatinib.
No muscle cramps adverse reaction or frequency in provided excerpts.
Low blood cell counts (anemia) are a common side effect of dasatinib.
Label excerpts discuss myelosuppression (severe thrombocytopenia/neutropenia/anemia) but do not provide “common” frequency or anemia as a specifically “common side effect.”
Low blood cell counts (thrombocytopenia) are a common side effect of dasatinib.
Label excerpts state severe thrombocytopenia/neutropenia/anemia occur earlier and more frequently in advanced phase, but do not support “common.”
Low blood cell counts (neutropenia) are a common side effect of dasatinib.
Same as above; frequency “common” not supported.
Serious side effects necessitate close monitoring by a healthcare professional.
Label excerpts recommend monitoring for specific warnings (e.g., PAH, QT, hepatotoxicity, myelosuppression/overdose), but do not support this generalized “necessitate close monitoring” wording as a standalone claim.
Dasatinib is a second-generation tyrosine kinase inhibitor.
Not addressed in provided label excerpts.
Dasatinib is often used when patients do not respond to or tolerate imatinib.
Label states resistance/intolerance to prior therapy including imatinib; it does not state “often used” wording.
Dasatinib has demonstrated higher response rates than imatinib in clinical trials.
Provided excerpts do not state response-rate comparisons vs imatinib.
Dasatinib sometimes provides faster responses than imatinib in clinical trials.
Provided excerpts do not state faster response claims.
Dasatinib has a different side effect profile compared to imatinib.
No imatinib comparative side-effect profile statement in provided excerpts.
Dasatinib is typically taken once a day.
Label specifies dosing as once daily, but “typically” is not needed; still broadly consistent. However this is not directly contradicted and is treated as generally supported rather than strictly supported.
Dosage of dasatinib can vary depending on the patient's response to the medication.
The excerpts show starting dose and interaction-driven dose adjustments and do not explicitly support “response-based” dose variability.
Dosage of dasatinib can vary depending on the patient's tolerance to the medication.
The excerpts include adverse reaction management concepts (reduce/withhold/discontinue for hepatotoxicity), but do not explicitly support this general “tolerance” phrasing as a broad rule.
Dasatinib treatment can produce significant rates of hematologic responses.
Provided excerpts do not state hematologic response rate language.
Dasatinib treatment can produce significant rates of cytogenetic responses.
Provided excerpts do not state cytogenetic response rate language.
Dasatinib treatment improved progression-free survival in patients compared to older treatment regimens or placebo in some instances.
No such PFS improvement statement in provided excerpts.
Dasatinib treatment improved overall survival in patients compared to older treatment regimens or placebo in some instances.
No such OS improvement statement in provided excerpts.
Relapse after stopping dasatinib can involve return of the underlying disease.
No discontinuation/relapse statement in provided excerpts.
Cancerous cells can proliferate again if dasatinib is stopped.
No discontinuation-related mechanistic/proliferation claim in provided excerpts.
Any decision to alter or stop dasatinib should be made in consultation with a hematologist.
Label excerpts do not provide such prescriber-consultation wording.
Stopping dasatinib treatment especially without medical supervision can lead to relapse of the leukemia.
No such relapse/discontinuation guidance in provided excerpts.
Contradictions
Important Omissions
Label-excerpt dose details (specific adult starting doses by indication: 100 mg vs 140 mg once daily; and tablet swallowing whole/no crushing; and guidance on timing with meals).
Importance:
Moderate
Drug interaction management details (avoid strong CYP3A4 inducers/inhibitors; avoid grapefruit juice; avoid H2 blockers/PPIs with SPRYCEL; antacid timing ≥2 hours before/after).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple safety-related claims are either generalized without label support (e.g., ‘common’ adverse reactions, generalized monitoring) or include discontinuation/relapse guidance not supported by the provided excerpts, which could misinform interpretation of risk/management. Core labeled warnings discussed (myelosuppression, bleeding, fluid retention, QT, hepatotoxicity, embryo-fetal toxicity, PAH) are not directly and accurately represented in most of the provided statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Numerous claims are not supported by the provided prescribing information excerpts, especially generic/patent availability, remission/relapse after stopping, comparative efficacy vs imatinib, and specific adverse reaction frequency statements.
Suggested Improvement
Restrict claims to what is present in the label excerpts: indications (adult/pediatric), specific labeled dosing (100 mg vs 140 mg once daily), administration instructions (swallow whole; meal flexibility), and label-supported safety topics (myelosuppression, bleeding-related events, fluid retention evaluation, QT prolongation correction, hepatotoxicity monitoring, PAH guidance) without unsupported frequency (“common”) or discontinuation/relapse assertions. Include labeled interaction specifics (CYP3A4 inhibitors/inducers, grapefruit juice, H2 blockers/PPIs avoidance, antacid timing).